China

CSPC will leverage its AI-powered drug discovery platform, which analyzes how target proteins bind with existing compounds to optimize and identify small molecules with the best potential for development.

Primary membranous nephropathy is an autoimmune disease characterized by the immune system attacking podocyte antigens in the kidneys, leading to the formation of immune complexes that damage kidney function.

Under the terms of the agreement, 3SBio and its subsidiaries—Shenyang Sunshine Pharmaceutical and 3S Guojian Pharmaceutical (Shanghai)—will grant Pfizer exclusive global rights to SSGJ-707, excluding China.

Russian experts bring experience in producing medical phantoms-models that mimic human tissues and organs used for equipment calibration and training, while their Chinese counterparts contribute advanced mathematical algorithms for signal processing.

Elevated levels of lipoprotein (a) are linked to a heightened risk of atherosclerotic cardiovascular disease, affecting approximately one in five adults worldwide, potentially leading to severe health problems, including heart attacks and strokes.

In this agreement, United Biotechnology will receive an upfront payment of US$200 million, with potential milestone payments from Novo Nordisk that could reach up to US$1.8 billion.

The new R&D center will prioritize early-stage research and clinical development, enhanced by data science and an AI lab.

The study highlighted the regimen’s effectiveness in maintaining viral suppression, with an impressive 94% of participants keeping their viral RNA levels below 50 copies/mL throughout the 24-week treatment period.